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Background: The RESTORE study, a multi-national randomized, placebo-controlled study,
showed that erdosteine – a muco-active antioxidant that modulates bacterial adhesiveness –
reduced the rate and duration of exacerbations in moderate and severe COPD with a history
of exacerbations. How much benefit patients with less severe disease experience when taking
this drug remains unclear.
Methods: This post hoc analysis of the 254 RESTORE participants with spirometrically-
defined moderate COPD (post-bronchodilator forced expiratory volume in 1 second [FEV1]
50‒79% predicted) examined exacerbation rate and duration, time to first exacerbation, and
exacerbation-free time. Data were analyzed using descriptive statistics and comparisons between
treatment groups used Wilcoxon rank-sum tests, Mann–Whitney U-tests, or log rank tests.
Results: PatientswithmoderateCOPD received erdosteine 300mg twice daily (n=126) or placebo
(n=128) added to usual COPD therapy for 12months. During this time, therewere 53 exacerbations
in the erdosteine group and 74 in the placebo group,with 42.1% and 57.8%of patients, respectively,
experiencing an exacerbation. There was a 47% reduction in the mean exacerbation rate with
erdosteine compared to placebo (0.27 vs 0.51 exacerbations per-patient per-year, respectively,
P=0.003), and a 58.3% reduction in themild exacerbation rate (0.23 vs 0.53mild exacerbations per-
patient per-year, P=0.001). Mean duration of exacerbations was 26% shorter in erdosteine-treated
patients (9.1 vs 12.3 days for placebo, P=0.022), with significant reductions in the duration of mild
andmoderate-to-severe exacerbations.Mean time tofirst exacerbationwas prolonged by 7.7% (182
days for erdosteine vs 169 days for placebo, P<0.001) and the mean exacerbation-free time was
increased by 51 days (279 days for erdosteine vs 228 days for placebo; P<0.001).
Conclusion: These results indicate that adding erdosteine to usual COPD maintenance
therapy reduces the number of mild, and duration of all, exacerbations in patients with
moderate COPD and a history of exacerbations.
Keywords: antioxidant, anti-inflammatory, chronic obstructive pulmonary disease,
erdosteine, COPD exacerbations
Plain-Language Summary
Patients with COPDoften experience exacerbations, when their symptomsworsen and they require
additional medication, emergency treatment, or hospital admission. A recent 1 year clinical trial
found that COPD patients with moderate or severe breathing problems and a history of exacerba-
tion events experienced fewer exacerbations if they took a medication called erdosteine, as well as
their usual treatment for COPD. This study reexamined the clinical trial data by looking only at the
group of patients with moderate breathing problems. The results showed that patients taking
erdosteine had fewer exacerbations that not only took longer to occur, but also lasted a shorter
amount of time. Thus, the overall burden of exacerbations was reduced in such patients. These
findings suggest that erdosteine may be a useful medication for patients with less severe COPD.
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Introduction
Exacerbations of COPD are significant events for patients
leading to a worse quality of life, use more health care
resources, and are at an increased risk of dying.1
Preventing exacerbations is an important goal of COPD
treatment,1,2 but exacerbation reduction remains subopti-
mal with current treatment strategies.3 As lung function
declines more rapidly in the early stages of the disease,4,5
and is accelerated by exacerbations,6,7 increasing treatment
intensity to prevent exacerbations in patients with moder-
ately severe airflow obstruction might be a useful treat-
ment strategy.
Exacerbations of COPD are generally classified as
mild, moderate, or severe according to the treatment and/
or health care resource use required in their management.8
The duration of exacerbations can vary widely, but longer
events are associated with greater morbidity, poorer health
status, hospitalization, an increased risk of recurrence, and
a faster decline in lung function.9–11 Time to first or sub-
sequent exacerbation has been used as an outcome mea-
sure in some clinical trials.12,13 Moreover, determining
exacerbation-free time is a useful way to assess the impact
of exacerbations.14
A variety of treatment approaches to prevent exacerba-
tions have been described,2 including medications that
improve lung mechanics,13,15 or use of anti-inflammatory
agents.16,17 The latter agents appear to be most effective in
individuals with higher blood eosinophil counts, who are
at increased risk of exacerbation.18,19 An alternative strat-
egy is to use antioxidant-based therapies. However, until
recently, the results of antioxidant therapy have largely
been confined to patients living in Asia and at doses higher
than recommended for safe use.20,21
Erdosteine is an oral mucoactive agent with antioxidant
and anti-inflammatory properties that also reduces bacterial
adhesiveness and enhances the effects of antibiotic therapy;22
all of these properties may be useful for the prevention and
treatment of COPD exacerbations. In the RESTORE
(Reducing Exacerbations and Symptoms by Treatment with
ORal Erdosteine in COPD) study,23 467 patients with spir-
ometrically-defined moderate or severe COPD (stage II/III
according to Global Initiative for Obstructive Lung Disease
[GOLD] 2007 definition) were randomized to receive erdos-
teine (300 mg twice daily) or placebo for 12 months in
addition to their usual COPD maintenance therapy.
Erdosteine treatment was associated with a reduction in the
rate and duration of exacerbations by 19.4% (P=0.01) and
24.6% (P=0.023), respectively, compared with placebo, but
there was no significant treatment effect on the time to first
exacerbation.23 The reduced exacerbation rate was primarily
due to a reduction in mild exacerbations.23
In the community setting, more than half of all COPD
patients (53.5%) have moderate COPD as defined using
spirometry (post-bronchodilator forced expiratory volume
in 1 second [FEV1] 50‒79% predicted).
24,25 In this post
hoc analysis of the RESTORE study, we aimed to determine
the effectiveness of erdosteine on COPD exacerbations in
the subgroup of patients who had spirometrically-defined
moderate COPD.
Methods
Study Design And Patients
The RESTORE study (NCT01032304) was a Phase III multi-
national, randomized, double-blind, placebo-controlled study
conducted in 10 European countries. Full details of the study
design, inclusion/exclusion criteria, ethical approval and
results have been reported.23 Briefly, following a 2-week run-
in period of continued usual COPD therapy, 467 patients with
moderate or severe COPD (grade II/III, GOLD 2007 classifi-
cation) were randomized to receive either oral erdosteine
(300mg twice daily, n=228) or placebo (n=239) for 12months
in addition to their usual COPD therapy. Written informed
consent was provided by each participant prior to enrolment.
The trial was conducted in accordance with the Declaration of
Helsinki and ethical approval was granted locally as outlined
in the Supplementary appendix.
For this post hoc analysis, we reclassified patients parti-
cipating in the RESTORE study using the spirometry criteria
from the GOLD 2017 guidelines.1 Thus, patients with mod-
erate COPD (GOLD 2) were defined as having a post-
bronchodilator FEV1 between 50% and 79% predicted, and
patients with severe COPD (GOLD 3) had a post-
bronchodilator FEV1 between 30% and 49% predicted; both
subgroups had a post-bronchodilator fixed ratio FEV1/forced
vital capacity [FVC] <0.70. Participants were outpatients
aged 40‒80 years, current or ex-smokers (≥10 pack-years),
on a stable therapeutic regimen for ≥8 weeks prior to inclu-
sion who had experienced ≥2 acute COPD exacerbations
requiring medical intervention in the previous 12 months,
but with no exacerbations in the preceding 2 months.
Outcome Measures
A COPD exacerbation was defined as a worsening of
symptoms beyond normal day-to-day variation that required
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a change in regular medication and/or health care resource
utilization.26 Exacerbations were confirmed by the investi-
gators from the variation in daily symptom (dyspnea,
cough, sputum) scores, changes in regular medication, use
of additional medication or emergency hospitalization for
COPD, as recorded in the patient diary. The severity of each
exacerbation was graded by investigators as mild, moderate
or severe (Table 1). The duration of an exacerbation was
determined from the diary card data. The onset of a COPD
exacerbation was defined by the presence of at least two
days of symptomatic worsening and/or an increased level of
health care utilization. Resolution of a mild exacerbation
was determined by a return to pre-event symptomatology.
Similarly, the end of a moderate or severe exacerbation was
determined as the cessation of additional treatment and
return to background therapy or hospital discharge and
return to background therapy. At least 10 consecutive days
without symptom variation and/or additional medication
and/or re-hospitalization since the previous episode were
required before a new event could be registered.
Exacerbation-free time was defined as the number of days
without an exacerbation present while the patient was par-
ticipating in the study. All diary card assessments were
conducted blind to treatment allocation as described in the
appendix to the primary publication23 and explained in the
supplement to this manuscript.
Other outcomes measured during the RESTORE study,
but not used in this post hoc analysis, include physician
assessment of disease severity, the St George’s Respiratory
Questionnaire, hospitalization rate, morning pre-dose FEV1,
FVC, use of reliever medication, and the 6-min walk test;
these have been reported in detail by Dal Negro et al.23
Safety assessments included monitoring adverse
events. Blood samples were collected at baseline (rando-
mization) and at the end of the study (after 12 months of
treatment) for evaluation of clinical laboratory parameters,
including blood eosinophil counts.
Statistical Analysis
All post hoc efficacy analyses were conducted using inten-
tion-to-treat (ITT) principles on randomized patients who
received at least one dose of study treatment and had at
least one available post-baseline efficacy evaluation.
Likelihood-based methods were used to handle missing
data. The adverse events reported for the moderate COPD
subgroupwere based on all patients randomized to treatment.
Baseline characteristics are reported using descriptive
statistics (means and standard deviations [SD] or percen-
tages). Comparisons between treatment groups were per-
formed using the chi-squared test followed by Fisher’s
exact test.
The frequency of exacerbations was analyzed using
a Poisson mixed regression model, with correction for over-
dispersion and including the following covariates: treatment,
age, sex, body mass index, and FEV1 at baseline, as
described previously.23,27 The COPD exacerbation rate over
the 12-month follow-up period was calculated as the mean
exacerbation rate per-patient per-year. Differences in exacer-
bation rates between treatment groups were analyzed non-
parametrically using the Wilcoxon rank-sum test (data are
reported as odds rations [OR] with 95% confidence inter-
vals [CI]).
The duration of an exacerbation was calculated as the
sum of days the patient was affected by a COPD exacerba-
tion, as defined earlier. Time to first exacerbation was calcu-
lated as the time in days from the beginning of the study to
the first exacerbation. Time free from exacerbation was cal-
culated as the difference between the total days the patient
was involved in the study and the number of days during
which the patient experienced a COPD exacerbation.
Comparisons between treatment groups used the Mann–
Whitney U-test for exacerbation duration and the log rank
test for time to first exacerbation.
All exacerbation analyses were repeated by concomi-
tant use/non-use of inhaled corticosteroids (ICS).
Table 1 Classification Of Exacerbation Severity In The RESTORE Study Based On Health Care Utilization26
Exacerbation
Severity
Level Of Health Care Utilization
Mild Patient has an increased need for medication (bronchodilators), which he/she can manage in own normal environment
Moderate Patient has increased need for medication (antibiotics and/or systemic corticosteroids) and feels the need to seek
additional medical assistance
Severe Patient/caregiver recognizes obvious and/or rapid deterioration in condition, requiring hospitalization or an emergency
department visit
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Blood eosinophil counts are summarized using descrip-
tive statistics. Exacerbation rate among patients with mod-
erate COPD was analyzed by stratification of baseline
blood eosinophil counts (<150 cells/μL and ≥ 150 cells/
μL) in keeping with previous reports in patients not using
dual bronchodilator therapy.19
Statistical analyses were performed using SPSS version
21.0 (IBM, Armonk, NY, USA). A two-sided P-value
<0.05 was considered nominally significant for all tests
in this post hoc analysis.
Results
Of the 407 patients randomized, 254 had a post-
bronchodilator FEV1 >50% predicted. Of these patients
with moderate COPD, 126 received erdosteine and 128
placebo, as detailed in the modified CONSORT figure
(Figure 1). The baseline characteristics of the subgroups
of patients in this post-hoc analysis are summarized in
Table 2 together with those of the total RESTORE
population.23 The patients receiving either erdosteine or
placebo were similar in this subgroup analysis but, as
expected, the FEV1 and FVC values were significantly
higher in the subgroup with moderate COPD than in the
subgroup with severe COPD, while ICS were used less
frequently in moderate COPD (Table 2).
There were 127 exacerbations during the 12 months of
treatment in the moderate COPD subgroup (n=254): 53 in
the erdosteine group (42.1% of patients) and 74 in the
placebo group (57.8% of patients).
In the subgroup of patients with moderate COPD, there
was a 47% reduction in the mean exacerbation rate with
erdosteine treatment compared to placebo (0.27 vs 0.51
exacerbations per-patient per-year; P=0.003; Figure 2):
OR: 0.53; 95% CI: 0.32‒0.87; P=0.017. This compares
to the 19.4% reduction seen for the total RESTORE popu-
lation (Figure 2). In contrast, there were no differences in
the exacerbation rate between active and placebo arms in
the patients with an FEV1< 50% predicted. In the sub-
group with moderate COPD, erdosteine treatment was
associated with a 58.3% reduction in the rate of mild
exacerbations (0.23 vs 0.53 mild exacerbations per-
patient per-year in the erdosteine and placebo groups,
respectively; OR: 0.41; 95% CI: 0.37‒0.54; P=0.001).
For the total RESTORE population, the reduction in the
rate of mild exacerbations was 57.1% (0.23 vs 0.54 mild
exacerbations per-patient per-year in the erdosteine and
placebo groups, respectively; P=0.002).23
The mean duration of exacerbations was 26% shorter
in patients with moderate COPD treated with erdosteine:
9.1 (SD 7.4) days compared with 12.3 (SD 9.6) days for
the placebo-treated patients (P=0.022) (Table 3). The dif-
ference between treatments was significant for the duration
of mild exacerbations and of moderate-to-severe exacer-
bations in this subgroup (Table 3). However, in the sub-
group with severe COPD, the duration of exacerbations
was similar for the erdosteine and placebo-treated patients
(Table 3). In addition, there was no difference in exacer-
bation frequency and duration between moderate COPD
patients who were ICS users and non-users (P>0.05)
(Supplementary Tables 1 and 2).
For patients with moderate COPD, the time to first
exacerbation was 7.7% longer in the erdosteine group:
mean 182 (SD 19) days vs 169 (SD 25) days in the
placebo group; difference between treatment groups 13
days (95% CI: 8.93‒17.07), P<0.001. The effect of erdos-
teine on the time to first exacerbation in this subgroup
was not influenced by the concomitant use of ICS
(Supplementary Table 3).
Mean exacerbation-free time during the study period
was significantly longer by a mean of 51 days (P<0.001)
in the erdosteine group compared with the placebo group
for the patients with moderate COPD, and by a mean of 39
days (P=0.008) for all RESTORE patients (Figure 3).
In both subgroups of patients with moderate COPD and
severe COPD, there were no significant differences in
blood eosinophil counts between treatment groups or
changes over time within each treatment group, but
patients with severe COPD had significantly higher eosi-
nophil counts than those with moderate COPD at both
time points and in both treatment groups (Supplementary
Table 4). Among patients with moderate COPD, the mean
exacerbation rate was higher in patients with blood eosi-
nophil counts ≥150 cells/μL, but erdosteine treatment sig-
nificantly reduced the mean exacerbation rate compared
with placebo in both subgroups with <150 cells/μL and
≥150 cells/μL (Figure 4).
A total of 305 adverse events were reported during the
study in the subgroup of patients with moderate COPD:
136 adverse events in the erdosteine group (3 serious
adverse events) and 169 in the placebo group (4 serious
adverse events). None of the serious adverse events was
considered treatment-related or resulted in patient death.
Erdosteine appeared to be well tolerated with no substan-
tial differences from placebo.
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Discussion
The RESTORE study demonstrated that erdosteine adminis-
tered twice daily at the licensed dose (300 mg) reduced the
overall exacerbation rate in COPD patients with a history of
exacerbations in the previous year, many of whom were
already receiving previously standard therapy with ICS.23
Randomized
n = 467
Allocated to erdosteine 
300 mg twice daily
n = 228
Lost to follow up n = 25 (11%)
Adverse Event n = 9 (4%)
Consent withdrawn n = 16 (7%)
Assessed for eligibility
n = 528
Excluded n = 61
Not meeting inclusion criteria n = 47

















Lost to follow up n = 26 (11%)
Adverse Event n = 6 (3%)
Consent withdrawn n = 20 (8%)
Allocated to placebo
n = 239
Figure 1 Patient disposition in RESTORE study.
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The primary report of the RESTORE study did not seek to
identify which subgroup of patients would benefit the most
from erdosteine treatment, so we addressed this issue in the
current exploratory post hoc analysis. The results suggest that
erdosteine use has a significant effect on exacerbations in
patients with less severe COPD defined spirometrically
(FEV1 50‒79%), as the relative effect of treatment on the
overall exacerbation rate was almost doubled compared to
placebo. A similar effect was seen on mild exacerbations
classified by treatment intensity, but there was no reduction
in the number of exacerbations observed in patients with
severe COPD. Similarly, the reduction in the duration of
mild exacerbations was most evident in patients with mod-
erate COPD. In this subgroup, erdosteine therapy was asso-
ciated with a significant increase in both the time to first
exacerbation and the total time without exacerbations in
patients with a history of exacerbations. Unlike other anti-
inflammatory agents, the positive effects of erdosteine were
not restricted to patients with a higher blood eosinophil
count. Encouragingly, there was no evidence of
a significant adverse event profile in these less impaired
COPD patients. These findings potentially impact the way
in which we view COPD exacerbations and for the treatment
options to be considered for preventing exacerbations.
Stratification of the treatment effect by baseline lung
function has been examined with other treatments known
to prevent COPD exacerbations, including inhaled
bronchodilators15 and long-acting inhaled bronchodila-
tor–ICS combinations.28 In general, categorizing patients
in this way has little impact on the overall efficacy of
these treatments, although the results of the FLAME
(Effect of Indacaterol Glycopyronium vs Fluticasone
Salmeterol on COPD Exacerbations) study indicated
that inhaled long-acting bronchodilator combination ther-
apy may be relatively less effective in patients with very
severe COPD (FEV1 <30% predicted, GOLD stage IV).
13
However, applying this approach to the RESTORE study
data gave a different answer. Although the ITT analysis
reported a 19% reduction in exacerbation rate of the total
study population, this difference was driven by patients in
the spirometrically-defined moderate COPD subgroup,
where a 47% reduction in exacerbation rate was seen
with erdosteine therapy compared to placebo. By con-
trast, there was little difference in the exacerbation rate
Table 2 Demographic And Baseline Characteristics Of Patients (ITT population)
Moderate COPDa (N=254) Severe COPDb (N=191) All RESTORE Patientsc (N=445)
Erdosteine Placebo Erdosteine Placebo Erdosteine Placebo
Patients, n 126 128 89 102 215 230
Age, years 64.8 (7.6) 66.1 (7.3) 62.9 (8.9) 63.1 (8.8) 63.8 (8.3) 64.1 (8.2)
Male, % 65.9 72.7 74.5 73.9 71.8 74.6
BMI, kg/m2 27.6 (5.0) 28.2 (5.6) 27.0 (4.8) 27.8 (5.1) 27.2 (5.3) 28.0 (5.4)
Smoking status, %
Current smoker 31.7 28.9 25.8 27.5 27.1 28.0
Ex-smoker 68.3 71.1 74.2 72.5 72.9 72.0
ICS,d n (%) 88 (69.8) 91 (71.1) 80 (89.9)* 94 (92.2)* 165 (75.8) 173 (75.2)
FEV1, L 1.61 (0.35) 1.68 (0.42) 1.26 (0.39) 1.23 (0.43) 1.43 (0.40) 1.46 (0.47)
FEV1, % predicted 59.88 (6.3) 61.08 (6.8) 47.21 (10.83) 46.72 (11.69) 51.45 (12.82) 54.38 (13.33)
FVC, L 2.82 (0.66) 2.89 (0.72) 2.59 (0.99)* 2.54 (0.97)* 2.74 (0.93) 2.74 (0.94)
Post-BD FEV1/FVC, ratio % 58.76 (8.8) 58.00 (8.1) 51.92 (9.88)* 50.81 (10.03)* 54.01 (11.3) 53.26 (10.8)
Notes: Data are presented as mean (standard deviation) unless indicated otherwise. aModerate COPD group determined post hoc based on GOLD 2011 spirometry
criteria (FEV1 50‒79% predicted); bSevere COPD group determined post hoc based on GOLD 2011 spirometry criteria (FEV1 30%‒49% predicted); cData from Dal Negro
et al;23dICS alone or combined with adrenergic agents. *P<0.05 versus moderate COPD group. (Categorical variables have been compared as continuous depending on the
distribution: if normal with t-tested for independent samples, if not normal with comparisons between treatment groups used the Mann–Whitney U-test). All comparisons
between the erdosteine and placebo groups were non-significant.
Abbreviations: BD, bronchodilator; BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroid; ITT,
intention-to-treat; NS, not significant for comparison between treatment groups.
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among patients with worse spirometry when erdosteine
therapy was compared with placebo. Although there were
fewer patients in this severe COPD subgroup, it seems
unlikely that the comparison is underpowered statistically
given the lack of difference in event rates between the
two treatment groups.
Recent reports have identified differences in the way that
exacerbations are treated dependent on the background ther-
apy taken.29 The SUMMIT (Study to Understand Mortality
and Morbidity) study included patients with spirometrically-
defined moderate COPD as in the RESTORE study but,























0,27       0,51                             1,43       1,41                               0,91      1,13
Figure 2 Exacerbation rate according to COPD severity subgroup and for all patients in the RESTORE study.
Table 3 Exacerbation Duration (In days) By Exacerbation Severity (Mild Or Moderate-To-severe), COPD Severity And Treatment Group
Erdosteine Placebo %Change P-value
Moderate COPD patients (N=254)
All exacerbations 9.1 (7.4) 12.3 (9.6) −26.0 (5.6) 0.022
Mild exacerbations 7.7 (4.9) 9.8 (8.0) −21.4 (5.0) 0.037
Moderate-to-severe exacerbations 10.5 (8.5) 13.7 (10.4) −23.4 (4.8) 0.040
Severe COPD patients (N=191)
All exacerbations 10.9 (7.5) 12.8 (9.9) −14.8 (4.7) 0.093
Mild exacerbations 8.7 (5.8) 10.4 (7.8) −16.3 (4.8) 0.131
Moderate-to-severe exacerbations 13.9 (9.8) 15.0 (11.2) −7.3 (3.4) 0.241
All RESTORE patients (N=445)
All exacerbations 9.5 (7.2) 12.6 (9.7) −24.6 (5.3) 0.023
Mild exacerbations 8.4 (5.2) 10.4 (8.2) −19.2 (4.9) 0.039
Moderate-to-severe exacerbations 11.1 (8.9) 14.1 (10.8) −21.3 (5.2) 0.041
Note: Data are presented as mean (standard deviation) in days.
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as we did and so data about mild events, where routine
treatment is intensified but new therapy is not started, were
not available in that large study.29 In the present analysis, we
found significant reductions in the duration of mild exacer-
bations in the subgroup of patients with moderate COPD
treated with erdosteine and this played an important role in
increasing the time to first event for all exacerbations.
Although meta-analysis of a number of studies of mucolytic
drugs suggest that they are useful in preventing COPD
exacerbations,30 such an effect has not been reported in
individual studies, which likely reflects their differing study
designs and inclusion criteria. Our findings of a longer time
to first exacerbation and a longer exacerbation-free time with
erdosteine in patients with spirometrically-defined moderate
COPD lends support to the major effect of this drug being in
patients with milder airflow obstruction.
A particular strength of the RESTORE study was the
prespecified recording of exacerbation duration. To date,
only regular macrolide therapy has been shown to decrease
exacerbation duration,31 which is a known risk factor for
subsequent hospitalization in COPD patients.14 As antici-
pated, exacerbations did not last as long in patients with
moderate COPD as compared to severe disease, and
exacerbations classified as mild were shorter than those
where antibiotics and/or corticosteroids were used.
However, in all these subgroups, erdosteine treatment
was associated with shorter exacerbation events compared
with placebo, a difference that was statistically significant
in patients with moderate spirometric impairment. Given
the greater variation in exacerbation duration in the sub-
group with severe COPD, it is likely that comparisons in
these patients are underpowered to detect a significant
difference; although, if present, the difference between
erdosteine and placebo groups is likely to be of smaller
magnitude than in the patients with moderate COPD.
Overall the total number of days that patients experienced
symptoms related to an exacerbation was lower in the
erdosteine treated subjects when compared to those receiv-
ing placebo in addition to their usual treatments. This may
be relevant as data from population studies and early
disease cohorts suggests that exacerbations including unre-
ported events have an important impact on patient health
























51 days (P<0.001) 39 days (P=0.008)
Figure 3 Exacerbation-free time (mean days) in patients with moderate COPD and for all patients in the RESTORE study.
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There has been much discussion about the use of the
blood eosinophil count as a stratifying variable when
selecting anti-inflammatory therapy for patients with
COPD. Like others we found that patients with higher
blood eosinophil counts experienced more exacerbations,
but unlike data obtained from patients treated with ICS
and roflumilast18,19 we saw no differential effect of treat-
ment based on eosinophil numbers. However, our event
rates were relatively low and we could not stratify for
higher eosinophil counts as was done in some other trials.
Nonetheless, the similarity of the mean data in the high
and low eosinophil groups supports the idea that erdos-
teine’s effects are not substantially influenced by the blood
eosinophil count.
Our study has several strengths beyond data collection of
mild exacerbation events. Erdosteine was well tolerated in
both subgroups of patients with moderate and severe COPD.
This likely reflects its use at licensed doses rather than the
high doses of other antioxidants, such as N-acetylcysteine
(NAC), which were needed to show an effect on exacerbation
rate in patients with COPD.21 Concerns about the potential of
further harm at high-dose NAC has led some investigators to
curtail clinical research with this formulation.34 As erdos-
teine had so few side effects there was no substantial differ-
ence in the withdrawal rate from either treatment arm (see
Figure 1), a factor that has complicated interpretation of other
studies.7,35 Our patients were predominantly Caucasian and
were using appropriate background medication throughout
the study, including ICS in 75% of patients. An earlier
European trial found no benefit of NAC in patients with
COPD who used ICS.36 In the present analysis, we found
no interaction between ICS use and the effects of therapy in
our patients with moderate COPD in terms of exacerbation
number or duration. Nonetheless, there are limitations to our
analysis. This is a pre-specified post hoc analysis and so the
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Figure 4 Exacerbation rate by blood eosinophil count (<150 cells/μL and ≥150 cells/μL) for patients with moderate COPD by treatment group.
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nominally significant. We did not have information that
would allow us to classify patients according to the current
GOLD system, so our patients must be considered to be in
either groups C or D of that classification system.1 The entry
criteria for the RESTORE study specified that patients should
have a prior exacerbation history, but the mean exacerbation
rate in the placebo arm of the study was lower than expected.
This is not unique to our study, having been seen in other
treatment studies with similar recruitment criteria.37,38 This
lower than expected exacerbation rate in the RESTORE
study may reflect an improved patient adherence to existing
therapy on study entry or the marked variability in exacerba-
tions over time as seen in recent reports from the large
SPIROMICS (SubPopulations and InteRmediate Outcome
Measures In COPD Study) and TIOSPIR (TIOtropium
Safety and Performance in Respimat®) studies, where
a large percentage of participants with a history of frequent
exacerbations did not subsequently experience these events
during 2–3 years of follow-up in the study.39,40 The use of
diary cards to define events can be criticized as being impre-
cise, but it has been used widely by other groups6,9–11 and the
methodology used here has been covered in detail in the
appendix to the original RESTORE publication23. Given
the blinded nature of the study we believe the data on number
and duration of events are likely to be correct.
This post hoc analysis has a number of clinical impli-
cations. It provides further evidence for the heterogeneity
of exacerbation events, at least in terms of their response
to therapy with differences in the ability of an oral anti-
oxidant like erdosteine to prevent events according to the
severity of the patient’s airflow obstruction and the type
of treatment thought necessary to manage the episode.
Whether this reflects differences in the etiology of the
exacerbations, the host response to the triggering factor,
or a combination of these two remains unclear. However,
the present results do emphasize the value of knowing the
severity of airflow obstruction when considering what
prophylactic therapy to prescribe as erdosteine did not
reduce the number of moderate or severe events reported
by our patients. Currently, there is renewed interest in the
factors in early COPD leading to disease progression,41
and a need to identify well tolerated treatments that can
be used earlier in the natural history of COPD than those
previously considered. Our data suggests that drugs like
erdosteine, which are orally active, well tolerated and can
prevent exacerbation events that are common in less
severe disease, may prove useful in the management of
the less severely impaired COPD patient with a history of
exacerbations.
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